查詢結果分析
相關文獻
- 淺談呼吸道細胞融合病毒及現行預防策略
- Immunochemical Studies on β[feb5]-Bungarotoxin
- 認識伊波拉病毒
- 呼吸道融合病毒新利器,疫苗、單株抗體面面觀
- 臺灣地區A型肝炎流行之演變與疫苗的成效
- 畜用免疫去勢方法的研發
- The Anti-Inflammatory Effect of a Long-Acting Theophylline (Unidur) in Patients with Bronchial Asthma
- Vaccine Storage Practices in Primary Care Physicians' Offices in Taiwan
- Comparison of Immunogenicity of Simultaneous and Nonsimultaneous Vaccination with MMR and JE Vaccine Among 15-month-old Children
- 水痘感染與水痘疫苗之預防接種
頁籤選單縮合
| 題 名 | 淺談呼吸道細胞融合病毒及現行預防策略=Update on Prevention Strategies for Respiratory Syncytial Virus Infection |
|---|---|
| 作 者 | 林明儒; 陳志榮; | 書刊名 | 感染控制雜誌 |
| 卷 期 | 35:2 2025.04[民114.04] |
| 頁 次 | 頁101-110 |
| 分類號 | 415.23 |
| 關鍵詞 | 呼吸道細胞融合病毒; 單株抗體; 疫苗; Respiratory syncytial virus; Vaccine; Monoclonal antibody; Pre-fusion F protein; |
| 語 文 | 中文(Chinese) |
| DOI | 10.6526/ICJ.202504_35(2).0004 |
| 中文摘要 | 呼吸道細胞融合病毒(Respiratory Syncytial Virus, RSV)是一種常見的病毒,主要影響嬰幼兒、老年人及免疫功能低下者,引起下呼吸道感染,如細支氣管炎和肺炎。早期疫苗臨床試驗發生的嚴重不良反應使疫苗開發停滯數十年。隨著科學家逐步瞭解RSV的免疫機制,近10年來學界發現RSV的前融合F蛋白(Pre-F)是最佳的免疫目標,能誘導高效中和抗體。以此為定基,自2023年以來,包括次蛋白單位及mRNA技術的疫苗陸續在臨床試驗取得成功並核准上市,為不同年齡層和高風險族群提供了多樣化更有效的預防選擇。本文將針對RSV的臨床表徵、流行病學以及現行的疫苗和單株抗體做一簡單的介紹。 |
| 英文摘要 | Respiratory Syncytial Virus (RSV) is a common virus that primarily affects infants, the elderly, and individuals with weakened immune systems, causing lower respiratory tract infections, such as bronchiolitis and pneumonia. Severe adverse reactions observed in early vaccine clinical trials led to a decades-long halt in vaccine development. With improvements in our understanding of the immune mechanisms of RSV, the pre-fusion F protein (Pre-F) has been identified as the optimal immunological target, capable of inducing highly effective neutralizing antibodies. Based on this breakthrough, since 2023, vaccines utilizing subunit protein and mRNA technology have achieved clinical success and received regulatory approval, providing a diverse and more effective range of preventive options for different age groups and high-risk populations. This article provides a brief overview of the clinical manifestations, epidemiology, and currently available vaccines and monoclonal antibodies for RSV. |
本系統中英文摘要資訊取自各篇刊載內容。